vs
Apellis Pharmaceuticals, Inc.（APLS）与AdvanSix Inc.（ASIX）财务数据对比。点击上方公司名可切换其他公司
AdvanSix Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.8倍（$359.9M vs $199.9M），AdvanSix Inc.净利率更高（-0.8% vs -29.5%，领先28.7%），AdvanSix Inc.同比增速更快（9.4% vs -5.9%），AdvanSix Inc.自由现金流更多（$36.1M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 3.4%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
AdvanSix Inc.是一家美国化工企业，主营尼龙6以及己内酰胺、硫酸铵肥料等相关化工产品。该公司原为霍尼韦尔旗下树脂与化工事业部，于2016年分拆独立，2019年预估营收达14亿美元，其企业历史可追溯至1884年在宾夕法尼亚州法兰克福成立的H. W. Jayne公司。
APLS vs ASIX — 直观对比
营收规模更大
ASIX
是对方的1.8倍
$199.9M
营收增速更快
ASIX
高出15.3%
-5.9%
净利率更高
ASIX
高出28.7%
-29.5%
自由现金流更多
ASIX
多$50.4M
$-14.3M
两年增速更快
APLS
近两年复合增速
3.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $359.9M |
| 净利润 | $-59.0M | $-2.8M |
| 毛利率 | — | 7.6% |
| 营业利润率 | -25.6% | -0.7% |
| 净利率 | -29.5% | -0.8% |
| 营收同比 | -5.9% | 9.4% |
| 净利润同比 | -62.2% | -892.9% |
| 每股收益（稀释后） | $-0.40 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSASIX
| Q4 25 | $199.9M | $359.9M | ||
| Q3 25 | $458.6M | $374.5M | ||
| Q2 25 | $178.5M | $410.0M | ||
| Q1 25 | $166.8M | $377.8M | ||
| Q4 24 | $212.5M | $329.1M | ||
| Q3 24 | $196.8M | $398.2M | ||
| Q2 24 | $199.7M | $453.5M | ||
| Q1 24 | $172.3M | $336.8M |
净利润APLSASIX
| Q4 25 | $-59.0M | $-2.8M | ||
| Q3 25 | $215.7M | $-2.6M | ||
| Q2 25 | $-42.2M | $31.4M | ||
| Q1 25 | $-92.2M | $23.3M | ||
| Q4 24 | $-36.4M | $352.0K | ||
| Q3 24 | $-57.4M | $22.3M | ||
| Q2 24 | $-37.7M | $38.9M | ||
| Q1 24 | $-66.4M | $-17.4M |
毛利率APLSASIX
| Q4 25 | — | 7.6% | ||
| Q3 25 | — | 6.8% | ||
| Q2 25 | — | 14.3% | ||
| Q1 25 | — | 14.2% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 14.4% | ||
| Q2 24 | — | 17.9% | ||
| Q1 24 | — | 0.9% |
营业利润率APLSASIX
| Q4 25 | -25.6% | -0.7% | ||
| Q3 25 | 48.7% | -0.9% | ||
| Q2 25 | -18.6% | 7.7% | ||
| Q1 25 | -50.0% | 7.7% | ||
| Q4 24 | -12.3% | -3.9% | ||
| Q3 24 | -24.0% | 7.5% | ||
| Q2 24 | -14.7% | 11.5% | ||
| Q1 24 | -36.0% | -7.0% |
净利率APLSASIX
| Q4 25 | -29.5% | -0.8% | ||
| Q3 25 | 47.0% | -0.7% | ||
| Q2 25 | -23.6% | 7.7% | ||
| Q1 25 | -55.3% | 6.2% | ||
| Q4 24 | -17.1% | 0.1% | ||
| Q3 24 | -29.2% | 5.6% | ||
| Q2 24 | -18.9% | 8.6% | ||
| Q1 24 | -38.5% | -5.2% |
每股收益（稀释后）APLSASIX
| Q4 25 | $-0.40 | $-0.11 | ||
| Q3 25 | $1.67 | $-0.10 | ||
| Q2 25 | $-0.33 | $1.15 | ||
| Q1 25 | $-0.74 | $0.86 | ||
| Q4 24 | $-0.30 | $0.02 | ||
| Q3 24 | $-0.46 | $0.82 | ||
| Q2 24 | $-0.30 | $1.43 | ||
| Q1 24 | $-0.54 | $-0.65 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $19.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $815.2M |
| 总资产 | $1.1B | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSASIX
| Q4 25 | $466.2M | $19.8M | ||
| Q3 25 | $479.2M | $23.7M | ||
| Q2 25 | $370.0M | $18.4M | ||
| Q1 25 | $358.4M | $8.3M | ||
| Q4 24 | $411.3M | $19.6M | ||
| Q3 24 | $396.9M | $17.3M | ||
| Q2 24 | $360.1M | $12.1M | ||
| Q1 24 | $325.9M | $20.6M |
总债务APLSASIX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSASIX
| Q4 25 | $370.1M | $815.2M | ||
| Q3 25 | $401.2M | $818.2M | ||
| Q2 25 | $156.3M | $823.7M | ||
| Q1 25 | $164.2M | $794.4M | ||
| Q4 24 | $228.5M | $774.6M | ||
| Q3 24 | $237.1M | $766.4M | ||
| Q2 24 | $264.3M | $746.6M | ||
| Q1 24 | $266.7M | $713.2M |
总资产APLSASIX
| Q4 25 | $1.1B | $1.7B | ||
| Q3 25 | $1.1B | $1.7B | ||
| Q2 25 | $821.4M | $1.6B | ||
| Q1 25 | $807.3M | $1.6B | ||
| Q4 24 | $885.1M | $1.6B | ||
| Q3 24 | $901.9M | $1.5B | ||
| Q2 24 | $904.5M | $1.5B | ||
| Q1 24 | $831.9M | $1.5B |
负债/权益比APLSASIX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $63.7M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $36.1M |
| 自由现金流率自由现金流/营收 | -7.1% | 10.0% |
| 资本支出强度资本支出/营收 | 0.1% | 7.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $6.4M |
8季度趋势，按日历期对齐
经营现金流APLSASIX
| Q4 25 | $-14.2M | $63.7M | ||
| Q3 25 | $108.5M | $26.6M | ||
| Q2 25 | $4.4M | $21.1M | ||
| Q1 25 | $-53.4M | $11.4M | ||
| Q4 24 | $19.4M | $64.2M | ||
| Q3 24 | $34.1M | $57.3M | ||
| Q2 24 | $-8.3M | $50.2M | ||
| Q1 24 | $-133.0M | $-36.2M |
自由现金流APLSASIX
| Q4 25 | $-14.3M | $36.1M | ||
| Q3 25 | $108.3M | $66.0K | ||
| Q2 25 | $4.4M | $-7.2M | ||
| Q1 25 | $-53.4M | $-22.6M | ||
| Q4 24 | $19.3M | $29.8M | ||
| Q3 24 | — | $26.8M | ||
| Q2 24 | $-8.4M | $16.7M | ||
| Q1 24 | $-133.3M | $-71.6M |
自由现金流率APLSASIX
| Q4 25 | -7.1% | 10.0% | ||
| Q3 25 | 23.6% | 0.0% | ||
| Q2 25 | 2.5% | -1.7% | ||
| Q1 25 | -32.0% | -6.0% | ||
| Q4 24 | 9.1% | 9.1% | ||
| Q3 24 | — | 6.7% | ||
| Q2 24 | -4.2% | 3.7% | ||
| Q1 24 | -77.3% | -21.3% |
资本支出强度APLSASIX
| Q4 25 | 0.1% | 7.7% | ||
| Q3 25 | 0.0% | 7.1% | ||
| Q2 25 | 0.0% | 6.9% | ||
| Q1 25 | 0.0% | 9.0% | ||
| Q4 24 | 0.0% | 10.4% | ||
| Q3 24 | 0.0% | 7.7% | ||
| Q2 24 | 0.0% | 7.4% | ||
| Q1 24 | 0.2% | 10.5% |
现金转化率APLSASIX
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | 0.67× | ||
| Q1 25 | — | 0.49× | ||
| Q4 24 | — | 182.29× | ||
| Q3 24 | — | 2.57× | ||
| Q2 24 | — | 1.29× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
